<DOC>
	<DOCNO>NCT01969877</DOCNO>
	<brief_summary>The primary endpoint study investigate difference overall survival patient locally advanced head neck cancer , randomize either radiotherapy cetuximab radiotherapy cisplatin . A second randomization perform patient T3-T4 tumor ; allocate radiotherapy either 68.0 Gy 73.1 Gy .</brief_summary>
	<brief_title>A Study Cisplatin Plus Radiotherapy Compared Cetuximab Plus Radiotherapy Locally Advanced Head Neck Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age least 18 year Histologically cytologically confirm , previous untreated head neck squamous cell cancer oral cavity , hypopharynx , larynx oral cavity aim unimodal treatment radiotherapy curative intent Tumor stage III IV , evidence distant metastases beyond regional node neck WHO/Eastern Cooperative Oncology Group ( ECOG ) performance status 02 The patient must expect withstand radiotherapy combine cisplatin cetuximab The patient must able understand information treatment give write informed concent participate trial Adequate followup study must possible ; exclude patient uncooperative Adequate renal function , creatinine clearance 50 ml/min/1.73 estimate accord local practice study centre Previous malignant disease head neck region , exception basal cell carcinoma curatively treat squamous cell carcinoma skin followup time least 3 year Concomitant previous malignancy . Exceptions adequately treat basal cell carcinoma squamous cell carcinoma skin , situ carcinoma cervix uterus , previous malignancy diseasefree interval least 5 year Two synchronous primary head neck squamous cell cancer time diagnosis Coexisting disease prejudice survival ( expect survival less 6 month ) Absolute neutrophil count le 1.5 x 109/L Platelet count le 100 x 109/L Bilirubin 1.5 time upper limit normal Aspartate aminotransferase ( ASAT ) Alanine aminotransferase ( ALAT ) 3 time upper limit normal Pregnancy lactation Allergy study drug excipients formulation Neuropathy grade 2 accord Common terminology criterion adverse event ( CTCAE ) v.4.0 Hearing loss/tinnitus relative exclusion criterion ; responsible physician decide whether patient may include study Severe cardiac illness ; myocardial infarction within 6 month prior randomization , severe congestive heart failure , severe cardiomyopathy , ventricular arrythmia , unstable angina , uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Quality life</keyword>
	<keyword>Human papilloma virus</keyword>
	<keyword>Health economy</keyword>
	<keyword>Biomarker investigation</keyword>
</DOC>